Difference between revisions of "Renal cell carcinoma, VHL-associated"
Jump to navigation
Jump to search
m (→References) |
|||
| Line 26: | Line 26: | ||
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
| − | | | + | |[https://doi.org/10.1056/nejmoa2103425 Jonasch et al. 2021 (MK-6482-004)] |
| − | |2018- | + | |2018-2019 |
| style="background-color:#91cf61" |Phase II (RT) | | style="background-color:#91cf61" |Phase II (RT) | ||
|- | |- | ||
|} | |} | ||
| − | |||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Belzutifan (Welireg)]] 120 mg PO once per day | *[[Belzutifan (Welireg)]] 120 mg PO once per day | ||
| Line 38: | Line 37: | ||
===References=== | ===References=== | ||
| − | # '''MK-6482-004:''' NCT03401788 | + | # '''MK-6482-004:''' Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. [https://doi.org/10.1056/nejmoa2103425 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/34818478/ Pubmed] NCT03401788 |
[[Category:Renal cell carcinoma regimens]] | [[Category:Renal cell carcinoma regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Renal cell carcinomas]] | [[Category:Renal cell carcinomas]] | ||
Revision as of 15:49, 27 November 2021
| Section editor | |
|---|---|
 |
Ali Raza Khaki, MD Stanford University Palo Alto, CA  arkhaki
|
Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.
1 regimens on this page
1 variants on this page
|
All lines of therapy
Belzutifan monotherapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Jonasch et al. 2021 (MK-6482-004) | 2018-2019 | Phase II (RT) |
Targeted therapy
- Belzutifan (Welireg) 120 mg PO once per day
Continued indefinitely
References
- MK-6482-004: Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. link to original article contains verified protocol Pubmed NCT03401788